U.S. Mortgage REITs Stock News

As February begins, the U.S. stock market has shown a strong start with major indices like the Dow Jones Industrial Average and S&P 500 posting significant gains, reflecting positive investor sentiment amid economic developments such as a new trade deal with India and expanding manufacturing activity. In this dynamic environment, identifying lesser-known stocks that demonstrate resilience and growth potential can be key to diversifying your portfolio effectively.

As February begins, U.S. stock markets have shown a robust performance with major indices like the Dow Jones and S&P 500 posting significant gains, reflecting a positive investor sentiment despite ongoing global economic uncertainties. In such an environment, dividend stocks can be an attractive option for investors seeking steady income and potential growth, as they combine regular payouts with the possibility of capital appreciation amidst fluctuating market conditions.

Freshworks Inc. ( NASDAQ:FRSH ) shareholders that were waiting for something to happen have been dealt a blow with a...

Key Insights Given the large stake in the stock by institutions, Hovnanian Enterprises' stock price might be vulnerable...

The Goosehead Insurance, Inc. ( NASDAQ:GSHD ) share price has fared very poorly over the last month, falling by a...

Monolithic Power Systems, Inc. ( NASDAQ:MPWR ) has announced that it will be increasing its dividend from last year's...

Esquire Financial Holdings, Inc. ( NASDAQ:ESQ ) will increase its dividend from last year's comparable payment on the...

In recent months, multiple law firms have filed securities class action lawsuits against Beyond Meat, alleging that between February 27 and November 11, 2025 the company made materially false and misleading statements about the valuation of certain long-lived assets and the likelihood of a significant non-cash impairment charge. The concentration of overlapping lawsuits, many on contingency fee arrangements, adds legal and financial pressure at a time when Beyond Meat is already managing...

Zoom Communications (ZM) is back in focus after partner Vizrt introduced InteractifAI and CaptivAIte, two AI driven tools that plug directly into Zoom Meetings to create more engaging, branded corporate communications. See our latest analysis for Zoom Communications. The recent AI focused tools from Vizrt arrive as Zoom Communications’ 7 day share price return of 7.06% and 30 day return of 11.52% outpace its 13.33% 1 year total shareholder return. This hints that short term momentum is...

Mirum Pharmaceuticals (MIRM) shares are in focus after Health Canada authorized LIVMARLI for cholestatic pruritus in patients with progressive familial intrahepatic cholestasis, expanding the drug’s reach in a rare pediatric liver disease. See our latest analysis for Mirum Pharmaceuticals. The Health Canada decision comes after a strong run in the share price, with Mirum’s 30 day share price return of 16.56% and 90 day share price return of 42.57% contributing to a very large 3 year total...

STERIS plc (NYSE:STE) is pursuing restructuring efforts and targeted acquisitions as it adapts to challenges in the medical technology and sterilization services sectors. These moves are intended to reshape operations and refine the company’s business mix in response to regulatory shifts and inflationary pressures. The changes highlight an effort to support operational flexibility and reinforce STERIS’s position across healthcare and sterilization services. For investors tracking NYSE:STE,...

DuPont de Nemours (DD) has drawn fresh attention after reporting fourth quarter and full year results that came in ahead of guidance, supported by cost discipline, productivity gains, and stronger profit margins. See our latest analysis for DuPont de Nemours. The earnings and guidance update comes after a strong run for DuPont de Nemours, with a 90 day share price return of 21.18% and a 1 year total shareholder return of 48.18%. This suggests momentum has been building rather than fading. If...

M&T Bank Corporation recently announced the appointment of Jeff Carpenter as Regional President of Massachusetts and, earlier this month, participated in the KBW 2026 Winter Financial Services Conference, with another investor presentation scheduled at the RBC Financial Institutions Conference in New York on March 10, 2026. By elevating an experienced Boston-focused banker and increasing its visibility at high-profile industry conferences, M&T is highlighting both its regional ambitions and...

VNET Group has acquired new power capacity in Ulanqab to support additional data center build out for AI workloads. The company is expected to secure a major hyperscale data center contract in China tied to this expanded capacity. These developments highlight VNET Group's role in supporting rising artificial intelligence infrastructure demand in China. VNET Group (NasdaqGS:VNET), trading at $12.07, is positioned at the center of growing data center and AI infrastructure needs in China. The...

The board of Air Products and Chemicals, Inc. ( NYSE:APD ) has announced that it will be paying its dividend of $1.81...

T-Mobile US (TMUS) is back in focus after extending its multi year partnership with Amdocs, just as investors gear up for the carrier’s upcoming earnings and closely watched guidance on margins. See our latest analysis for T-Mobile US. The extended Amdocs partnership and upcoming earnings are drawing fresh attention to T-Mobile US at a time when its 1 year total shareholder return of 21.71% decline contrasts with a 5 year total shareholder return of 69.20%. This hints at fading near term...

Kymera Therapeutics recently initiated dosing in its BREADTH Phase 2b trial of KT-621 for moderate to severe eosinophilic asthma and continues its BROADEN2 Phase 2b study in atopic dermatitis, advancing its oral STAT6 degrader program across Type 2 inflammatory diseases. This progress in parallel Phase 2b trials positions KT-621 as a potential platform therapy across multiple high-burden Type 2 conditions, which could influence how investors assess Kymera’s pipeline breadth and clinical...

Amentum Holdings (AMTM) opened Q1 2026 with revenue of about US$3.2b and net income of US$44m, translating to basic EPS of US$0.18, as the market weighs these numbers against a share price around US$32.06. Over recent quarters, the company has seen revenue move from US$3.4b in Q1 2025 to US$3.9b in Q4 2025 and then to US$3.2b in Q1 2026, while basic EPS shifted from US$0.05 to US$0.16 over the same 2025 span before landing at US$0.18 this quarter. This sets up a story where profitability...

We wouldn't blame Powell Industries, Inc. ( NASDAQ:POWL ) shareholders if they were a little worried about the fact...

Transocean (NYSE:RIG) has agreed to acquire Valaris in an all stock merger, creating what management describes as the world’s largest offshore drilling company. The deal brings together two major offshore drillers and combines their rig fleets, geographic reach, and customer bases. The companies highlight expected cost synergies and a larger, more diversified contract portfolio as key benefits of the transaction. For you as an investor, this move comes with NYSE:RIG trading at $5.44, after...

If you are wondering whether Zebra Technologies at around US$256.57 is a bargain or a value trap, you are not alone, as the share price and the fundamentals are sending some very mixed signals. Over the past week the stock is up 10%, yet the 30 day return is a 1.1% decline and the longer term record shows returns of 3.3% year to date, a 27.6% decline over 1 year and a 47.2% decline over 5 years. Recent coverage has focused on how investors are reassessing hardware focused tech names like...

Those following along with Fidelity D & D Bancorp, Inc. ( NASDAQ:FDBC ) will no doubt be intrigued by the recent...

Krystal Biotech received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for KB707, an inhaled, redosable immunotherapy for advanced non small cell lung cancer. The designation is based on early clinical evidence that KB707 may provide meaningful antitumor activity in advanced or metastatic NSCLC. RMAT status can create a faster and more flexible regulatory path for therapies targeting serious or life threatening conditions. For Krystal Biotech, ticker NasdaqGS:KRYS, this...

ImmunityBio (NasdaqGS:IBRX) is participating in the 2026 ASCO Genitourinary Cancers Symposium, highlighting its work in cancer immunotherapies. The company recently expanded use of its therapy Anktiva for lung cancer patients in Saudi Arabia following regulatory approval. ImmunityBio launched the ResQ215B Phase 2 trial, studying a chemotherapy free regimen for B cell non Hodgkin lymphoma. ImmunityBio focuses on developing cancer immunotherapies that aim to work with the immune system rather...